Lawrence F. Eichenfield, MD; Anthony J. Mancini, MD, FAAP, FAAD; Gaspar Rivera, MD, MPH, FAAP
This activity is jointly provided by Global Education Group and Integritas Communications.
This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
The educational design of this activity addresses the needs of pediatricians and other clinicians who treat pediatric and adolescent patients with moderate-to-severe atopic dermatitis.
Statement of Need/Program Overview
Atopic dermatitis is a common, chronic, inflammatory disease that manifests primarily in the skin, although research has uncovered potentially deleterious effects in other organ systems throughout the body.1,2 The disease-related physical and biopsychosocial burdens of this condition can have substantial effects on patient and parent/caregiver quality of life, particularly in pediatric and adolescent patients with moderate-to-severe disease.3,4 A better understanding of disease etiology has supported the development of new approaches to disease characterization and targeted therapies.5,6 As a result, the first biologic therapy is now available to treat adult patients with moderate-to-severe disease. Further, this biologic therapy and other advanced treatments are currently under investigation for pediatric and adolescent patients, with some positive outcomes recently reported.7-9 With novel therapies emerging for pediatric and adolescent patients with difficult-to-treat atopic dermatitis, attendees will benefit from updates on the latest clinical trial data, treatment guidelines, and practical recommendations on how to translate this information into daily clinical decision-making.10 In this Collaborative Care Symposium™, a panel of recognized pediatric dermatology experts will review the latest evidence with the goal of providing recommendations to enhance overall patient outcomes. The faculty panel will discuss the pathophysiologic underpinnings of atopic dermatitis, best practices in comprehensive patient evaluations, and the latest evidence relating to disease management and referral for young patients with moderate-to-severe disease.
- Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015:66(suppl 1):8-16.
- Brunner PM, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. JInvest Dermatol. 2017;137(1):18-25.
- Carroll CL, et al. The burden of atopic dermatitis: impact on the patient, family, and society.Pediatr Dermatol. 2005;22(3):192-199.
- Drucker AM, et al. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26-30.
- Mansouri Y, Guttman-Yassky E. Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics. J Clin Med. 2015;4(5):858-873.
- Gandhi NA, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov.2016;15(1):35-50.
- Paller, AS, et al. Therapeutic pipeline for atopic dermatitis: end of the drought? J Allergy Clin Immunol. 2017;140(3):633-643.
- Simpson EL, et al. Dupilumab efficacy and safety in adolescents with moderate-to-severe atopic dermatitis: results from a multicenter, randomized, placebo-controlled, double-blind, parallel-group, phase 3 study. Presented at the 27th EADV Congress. September 12-16, 2018, Paris, France. Poster #4640.
- Cotter DG, et al. Emerging therapies for atopic dermatitis: JAK inhibitors. J Am Acad Dermatol. 2018;78(3 suppl 1):S53-S62.
- Ariëns LFM, et al. Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy. Ther Adv Chronic Dis.2018;9(9):159-170.
After completing this activity, the participant should be better able to:
- Describe the pathophysiologic mechanisms and risk factors associated with atopic dermatitis, including the rationales for targeted therapies
- Longitudinally assess children and adolescents with atopic dermatitis for uncontrolled symptoms, comorbid conditions, and other biopsychosocial consequences for patients and their families
- Discuss the clinical profiles, trial data, and prescribing considerations for targeted therapies for pediatric and adolescent patients with moderate-to-severe atopic dermatitis
- Individualize therapeutic regimens for moderate-to-severe atopic dermatitis across pediatric health care settings based on ongoing symptoms, burdens, comorbidities, and shared clinical decision-making
Lawrence F. Eichenfield, MD
Professor of Dermatology and Pediatrics
Vice Chair, Department of Dermatology
Chief, Pediatric and Adolescent Dermatology
Rady Children’s Hospital
University of California, San Diego, School of Medicine
San Diego, California
Anthony J. Mancini, MD, FAAP, FAAD
Head, Division of Dermatology, Ann & Robert H. Lurie Children’s Hospital of Chicago
Professor of Pediatrics and Dermatology
Northwestern University Feinberg School of Medicine
Gaspar Rivera, MD, MPH, FAAP
San Ysidro Health
Chula Vista, California
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.
Physician Credit Designation
Global Education Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must score 70% or better on the posttest and complete the program evaluation.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Lawrence F. Eichenfield, MD: Consultant: Allergan Plc; Anacor Pharmaceuticals Inc.; Dermavant Sciences, Inc.; Dermira, Inc.; DS Biopharma Limited; Eli Lilly and Company; Forté Pharma Laboratories; Galderma Laboratories, L.P.; Incyte Corporation; LEO Pharma, Inc.; MatriSys Bioscience, Inc.; Medimetriks Pharmaceuticals, Inc.; Menlo Therapeutics Inc.; Novan, Inc.; Novartis AG; Ortho Dermatologics, Inc.; Otsuka Pharmaceutical Co., Ltd.; Pfizer Inc.; Regeneron Pharmaceuticals; Sanofi Genzyme; TopMD; DSM: Glenmark Pharmaceuticals Inc.; Investigator: LEO Pharma, Inc.; Regeneron Pharmaceuticals; Sanofi Genzyme; Advisory Board: Ortho Dermatologics, Inc. Equity Options: TopMD; Honoraria: Allergan Plc; Anacor Pharmaceuticals Inc.; Dermavant Sciences, Inc.; Dermira, Inc.; DS Biopharma Limited; Eli Lilly and Company; Forté Pharma Laboratories; Galderma Laboratories, L.P.; Glenmark Pharmaceuticals Inc.; Incyte Corporation; LEO Pharma, Inc.; MatriSys Bioscience, Inc.; Medimetriks Pharmaceuticals, Inc.; Menlo Therapeutics Inc.; Novan, Inc.; Novartis AG; Ortho Dermatologics, Inc.; Otsuka Pharmaceutical Co., Ltd.; Pfizer Inc.; Regeneron Pharmaceuticals; Sanofi Genzyme; Speakers Bureau: Ortho Dermatologics, Inc.
Anthony Mancini, MD. FAAP, FAAD: Consultant: Pfizer Inc.; Verrica Pharmaceuticals Inc.
Gaspar Rivera, MD, MPH, FAAP: Nothing to disclose
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Stacey Ullman, MHS: Nothing to disclose
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.